利伐沙班治疗效果

Deep vein thrombosis is a serious vascular disease. This type of disease will cause serious troubles to the patient's health and requires active medication for treatment. It is one of the commonly used therapeutic drugs in clinical practice. So what is the therapeutic effect of rivaroxaban?

Rivaroxaban significantly reduced the combined risk of stroke, cardiovascular death and heart disease by 24% in patients with chronic coronary or peripheral artery disease.

The major breakthrough is that the combination therapy of rivaroxaban at an arterial dose of 5 mg twice a day and aspirin 100 mg once a day has unprecedentedly reduced the relative risk of stroke by 42% and the risk of cardiovascular death by 22% compared with aspirin alone.

Bleeding rates were low, and although major bleeding increased, no significant increase in intracranial or fatal bleeding was evident.

The combination therapy significantly increased the net clinical benefit by 20%.

Rivaroxaban is highly effective and is used to prevent venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Rivaroxaban is suitable for adults with deep vein thrombosis and non-valvular atrial fibrillation.

The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents.

For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a missed dose occurs, the patient should take rivaroxaban immediately and continue taking the drug once a day the next day. Patients can take rivaroxaban with a meal or on its own.

Who can take rivaroxaban?

(1) Adult patients undergoing elective hip or knee replacement surgery.

(2) Adult patients with deep vein thrombosis (DVT) and pulmonary embolism (PE).

(3) Adult patients with non-valvular atrial fibrillation who have one or more risk factors (such as heart failure, hypertension, age ≥75 years, diabetes, stroke or transient ischemic attack) are eligible.